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Background: The optimal timing of coronary intervention in pa-
tients with non–ST-segment elevation acute coronary syndromes
(NSTE-ACSs) is a matter of debate. Conflicting results among pub-
lished studies partly relate to different risk profiles of the studied
populations.
Purpose: To do the most comprehensive meta-analysis of current
evidence on early versus delayed invasive treatment in NSTE-ACS.
Data Sources: MEDLINE, PubMed Central, and Google Scholar
databases; conference proceedings; ClinicalTrials.gov registry; and
Current Controlled Trials registry through May 2012.
Study Selection: Available randomized, controlled trials (RCTs) and
observational studies comparing early versus delayed intervention in
the NSTE-ACS population.
Data Extraction: Data were extracted for populations, interven-
tions, outcomes, and risk of bias. All-cause mortality was the pre-
specified primary end point. The longest follow-up available in each
study was chosen. The odds ratio with 95% CI was the effect
measure.
Data Synthesis: Seven RCTs (5370 patients) and 4 observational
studies (77 499 patients) were included. Early intervention was less
than 20 hours after hospitalization or randomization for RCTs and
24 hours or less for observational studies. Meta-analysis of the
RCTs was inconclusive for a survival benefit associated with the
early invasive strategy (odds ratio, 0.83 [95% CI, 0.64 to 1.09];
P  0.180); a similar result emerged from the observational studies.
With early versus late intervention, the odds ratios in the RCTs
were 1.15 (CI, 0.65 to 2.01; P  0.63) and 0.76 (CI, 0.56 to 1.04;
P  0.090) for myocardial infarction and major bleeding during
follow-up, respectively.
Limitation: Current evidence from RCTs is limited by the small
overall sample size, low numbers of events in some trials, and
heterogeneity in the timing of intervention and in patient risk
profiles.
Conclusion: At present, there is insufficient evidence either in favor
of or against an early invasive approach in the NSTE-ACS popula-
tion. A more definitive RCT is warranted to guide clinical practice.
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Invasive coronary revascularization has been shown to besuperior to conservative medical treatment in patients
with non–ST-segment elevation acute coronary syndromes
(NSTE-ACSs) and is recommended by international
guidelines (1–3), but the optimal timing of intervention
remains unclear; for example, data conflict about whether
catheterization needs to be done early (within 20 to 24
hours) or whether it can safely be delayed while the patient
receives medical therapy. In a recent meta-analysis of clin-
ical trials published through 2009, we reported that, in
patients with NSTE-ACS, a routine early invasive inter-
vention strategy did not significantly improve outcomes
compared with a delayed approach (4), but the CIs around
our estimates were wide and we could not exclude a clini-
cally relevant benefit of early invasive intervention. We up-
dated our literature review into 2012 and reviewed obser-
vational studies in an attempt to more thoroughly summarize
the literature comparing early versus delayed invasive revas-
cularization in patients with NSTE-ACS.
METHODS
The previous meta-analysis (4) and this update were
done according to established methods (5, 6) and in adher-
ence to the PRISMA (Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses) statement for report-
ing systematic reviews and meta-analyses in health care
interventions (7). Neither the original review nor the up-
date was based on a written protocol or registered in a
review registry.
Literature Search
An updated PRISMA flow chart providing detailed
descriptions of publication screening and reasons for exclu-
sion is shown in Appendix Figure 1 (available at www
.annals.org). We repeated our search of MEDLINE (Ap-
pendix Table 1, available at www.annals.org), PubMed
Central, and Google Scholar and conference proceedings
from the American College of Cardiology, American Heart
Association, European Society of Cardiology, Transcathe-
ter Cardiovascular Therapeutics, and European Association
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of Percutaneous Cardiovascular Interventions scientific ses-
sions to identify observational studies published between
November 1994 and May 2012 and randomized, con-
trolled trials (RCTs) published since our last search ended
(24 September 2010) (4). We also searched clinical trial
registries (www.clinicaltrials.gov and www.controlled-trials
.com) for unpublished studies.
Selection Criteria and Internal Validity
Inclusion criteria for RCTs included a diagnosis of
NSTE-ACS and allocation to early or delayed coronary
revascularization, where early intervention was defined as
coronary revascularization (percutaneous coronary inter-
vention [PCI] or coronary artery bypass grafting based on
angiographic characteristics and physicians’ clinical judg-
ment) less than 20 hours after hospitalization or random-
ization. Delayed intervention was defined as pretreatment
using standard medical therapy and subsequent revascular-
ization 20 hours or more after enrollment. The 20-hour
threshold was chosen because it clearly distinguished early
from delayed intervention groups in the trials. Studies
comparing invasive (20 hours) versus conservative strat-
egies or selective intervention done only in case of refrac-
tory angina were excluded from the analysis.
Inclusion criteria for observational studies included a
diagnosis of NSTE-ACS and allocation to early or delayed
coronary revascularization. We used a threshold of 24
hours to distinguish early from delayed intervention in ob-
servational studies because it best distinguished early from
delayed intervention in the 4 studies with that design.
Data were abstracted on prespecified forms by 2 inde-
pendent investigators not involved in any of the retrieved
studies. Internal validity was independently appraised by 2
investigators, and divergences were resolved by discussion
with a third investigator.
The potential risk of bias of RCTs was appraised by 2
unblinded investigators according to the Cochrane Collab-
oration guidelines (concealment of treatment allocation;
blinding of participants, personnel, or outcome assessors;
adequate assessment of incomplete outcome data; presence
of selective outcome reporting; and other potential sources
of bias). Nonrandomized studies were evaluated using the
Newcastle–Ottawa Scale for cohort studies (representative-
ness of the exposed cohort, selection of the nonexposed
cohort, ascertainment of exposure, and demonstration that
outcomes were not present at study start), cohort compa-
rability, and outcomes (means, duration, and adequacy of
assessment) (5).
Study End Points
As in our original review (4), overall mortality was the
primary end point and recurrent myocardial infarction
(MI), major bleeding complications, refractory ischemia,
and repeated revascularization were secondary end points.
Recurrent MI was defined as new or recurrent ischemic
symptoms lasting more than 20 minutes and an increase of
the creatine kinase–MB (CK-MB) level to greater than 2
times the upper limit of normal or electrocardiographic
changes (transient ST-segment depression or elevation
0.1 mV in 2 contiguous leads or development of new
pathologic Q-waves in 2 contiguous leads); most studies
used a CK-MB enzyme rather than troponin as the bio-
marker of necrosis. Major bleeding was defined using the
Thrombolysis in Myocardial Infarction criteria (intracra-
nial hemorrhage, a 5-g/dL decrease in the hemoglobin
concentration, or a 15% absolute decrease in the hemat-
ocrit) or as defined by trial or study investigators. Refrac-
tory ischemia was defined in only 1 study (8) as recurrent
ischemic symptoms lasting more than 5 minutes while the
patient received optimal medical therapy (2 antiangina
treatments) with documented characteristic electrocardio-
graphic changes indicative of ischemia and requiring addi-
tional intervention.
For each end point, the longest follow-up available in
each study was chosen.
Data Synthesis and Analysis
Data were analyzed according to the intention-to-treat
principle. Odds ratios (ORs) and 95% CIs were used as
summary statistics. Heterogeneity was assessed by the
Cochran Q test. Statistical heterogeneity was summarized
by the I2 statistic, which quantifies the percentage of vari-
ation in study results that is due to heterogeneity rather
than chance (9). Pooled ORs were calculated using the
DerSimonian and Laird random-effects model. In case of 0
outcome events, the continuity correction approach was
done by adding a correction factor of 0.5 to the number of
events and nonevents in each intervention group (10).
We did 2 additional sets of analyses: one in which we
assessed the influence of each study on estimates of effect
by removing each and assessing the effect of the removal on
the effect estimate, and another in which we included
events from 2 groups (immediate [2 hours] and early [10
to 48 hours]) from a 3-group trial (comparing immediate,
early, and delayed intervention). Review Manager, version
5.1 (The Nordic Cochrane Centre, Copenhagen, Den-
mark), and SPSS, version 15 (SPSS, Chicago, Illinois),
were used for statistical computations.
Role of Funding Source
This study did not receive external funding.
RESULTS
Study and Patient Characteristics
We screened 8472 potentially relevant articles and
identified 22 potentially relevant studies. After 11 exclu-
sions we had 7 RCTs (8, 11–16) (2 new to this update [14,
16]) and 4 observational studies (17–20) (all new to this
update) (Appendix Figure 1). None of the observational
studies was primarily designed to assess timing of
interventions.
The RCTs enrolled 5370 patients; 2799 were ran-
domly assigned to early and 2571 to delayed invasive in-
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tervention. For the 3-group trial (LIPSIA-NSTEMI
[Leipzig Immediate Versus Early and Late Percutaneous
Coronary Intervention Trial in Non–ST-Segment Eleva-
tion Myocardial Infarction]), which compared immediate,
early, and delayed invasive interventions, the immediate
and delayed intervention groups most closely matched the
early and delayed interventions of other trials, and we in-
cluded data from those in our primary analysis. Trial char-
acteristics are summarized in Table 1; additional patient
and trial characteristics are shown in Appendix Table 2
(available at www.annals.org). The time of the invasive
approach ranged in RCTs from 0.5 to 14 hours after ran-
domization (early intervention) and from 20.5 to 86 hours
(delayed intervention). Follow-up duration was the same
for all end points in each study except LIPSIA-NSTEMI,
which reported rates of major bleeding in the hospital
phase but rates of death and MI up to 6 months. Most
patients treated by coronary revascularization had PCI, and
some had coronary artery bypass grafting. Patients ran-
domly assigned to early versus delayed intervention were
well-matched for demographic and clinical characteristics.
Use of glycoprotein IIb/IIIa inhibitors was similar between
study groups, except in the ELISA (Early or Late Interven-
tion in Unstable Angina) trial, which did not prescribe the
agents for the early intervention group.
Two of the 4 observational studies (ACUITY [Acute
Catheterization and Urgent Intervention Triage Strategy]
and SYNERGY [Superior Yield of the New Strategy of
Enoxaparin, Revascularization and Glycoprotein IIb/IIIa
Inhibitors]) were post hoc analyses of RCTs originally de-
signed to compare antithrombotic strategies (17, 18) and
the other 2 were analyses of large registry databases
(CRUSADE [Can Rapid Risk Stratification of Unstable
Angina Patients Suppress Adverse Outcomes With Early
Implementation of the American College of Cardiology/
American Heart Association Guidelines] and GRACE
[Global Registry of Acute Coronary Events]) (19, 20) (Ta-
ble 2). The median timing of intervention reported in the
observational studies was 24 hours or less in the early
group versus more than 24 hours in the delayed group.
Mortality was reported in all 4 observational studies in-
volving 77 499 patients, whereas data on MI and major
bleeding were available in 3 studies (Table 2). In the
CRUSADE study, weekend versus weekday was used as an
“instrumental variable” to objectively reflect early versus
delayed timing of the invasive approach, which was in fact
the real comparison, given the shorter interval during
weekdays (median, 23.4 hours) versus weekends (median,
46.3 hours), thereby offering a quasi-randomization de-
sign. In the observational studies, adjusted estimates were
not always available and the measures of effect were heter-
ogeneous; therefore, unadjusted ORs, derived from the
event rates and the total number of patients in each group,
were used for the present analysis; on the other hand, as
shown in Appendix Table 3 (available at www.annals.org),
Table 1. Timing of the Invasive Approach, Definitive Treatment, and Clinical Outcomes at Follow-up for Randomized, Controlled
Trials Comparing Early and Delayed Strategies
Study, Year
(Reference)
Trial Name Median Time of
Catheterization, h










Early Strategy Delayed Strategy
Mehta et al,
2009 (8)






Death, MI, major bleeding,
re-PCI, refractory
ischemia at 6 mo
Montalescot et al,
2009 (11)






Death, MI, major bleeding,
re-PCI, refractory
ischemia at 1 mo
Neumann et al,
2003 (12)











OPTIMA 0.5 25 73 69 PCI: 73 (100) PCI: 69 (100) Death, MI, major bleeding,
re-PCI at 6 mo
Thiele et al,
2012 (14)







ischemia at 6 mo,
in-hospital major
bleeding
van ’t Hof et al,
2003 (15)

















Death, MI, major bleeding,
re-PCI, refractory
ischemia at 6 mo
ABOARD  Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention; CABG  coronary artery
bypass graft; ELISA  Early or Late Intervention in Unstable Angina; ISAR-COOL  Intracoronary Stenting With Antithrombotic Regimen Cooling Off; LIPSIA-
NSTEMI  Leipzig Immediate Versus Early and Late Percutaneous Coronary Intervention Trial in Non–ST-Segment Elevation Myocardial Infarction; MI  myocardial
infarction; NA  not available; PCI  percutaneous coronary intervention; TIMACS  Timing of Intervention in Acute Coronary Syndromes.
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the clinical variables were well-balanced between the 2
strategies, thus mitigating this potential limitation.
Risk of Bias of Included Studies
The RCTs were similar in their risk of bias (Appendix
Table 4, available at www.annals.org). All were done ac-
cording to the intention-to-treat principle; losses to
follow-up were infrequent and described in detail. Out-
comes were adjudicated by blinded central committees. In
the OPTIMA trial, the methods for random-sequence gen-
eration and allocation concealment were unclear. Except
for ELISA, which was a single-center study, and the ISAR-
COOL (Intracoronary Stenting With Antithrombotic Reg-
imen Cooling Off) trial, which was conducted at 2 sites,
the RCTs and observational studies were multicenter stud-
ies. Patients and providers were not blinded to the timing
and identity of interventions, a feature common to trials of
coronary angiography.
The patient populations of the observational studies
seemed to be representative of a contemporary patient with
NSTE-ACS having invasive management; the study partic-
ipants allocated to early or delayed intervention seemed
similar and were generally well-matched for clinical char-
acteristics and concomitant therapies; the assessment of
clinical outcomes was checked by an independent events
committee or by using standardized case report forms; on
the other hand, follow-up duration varied, ranging from
the in-hospital phase up to 1 year. The ACUITY study was
originally designed to compare the efficacy and safety of
heparin plus a glycoprotein IIb/IIIa inhibitor, bivalirudin
plus a glycoprotein IIb/IIIa inhibitor, and bivalirudin alone
in 13 819 patients with NSTE-ACS having angiography
within 72 hours of hospitalization. The SYNERGY study
was designed to compare enoxaparin or unfractionated
heparin in 10 027 patients with NSTE-ACS having an-
giography. Both were large, multicenter studies with ade-
quate methods, follow-up, and recording of patient char-
acteristics; on the other hand, selection bias may have
occurred with regard to PCI and its timing; indeed, precise
reasons for delaying PCI were not prospectively collected.
The GRACE and CRUSADE studies were prospective in-
ternational multicenter registries conducted to improve the
quality of care of patients with ACS, reflecting a high-risk
population from the real world. They mainly assessed gen-
eral items in the ACS setting and had fewer data available
on timing of the invasive approach. The main characteris-
tics and potential risk of bias of the 4 observational studies
are reported in Appendix Table 5 (available at www
.annals.org).
Mortality
Individual and pooled ORs for mortality in the RCTs
are shown in Figure 1. One-hundred-ten of 2799 patients
(3.9%) in the early invasive groups died compared with
120 of 2571 patients (4.7%) in the delayed invasive groups
(OR, 0.83 [95% CI, 0.64 to 1.09]; P  0.180; heteroge-
neity P  0.58; I2  0%). The pooled estimate from ob-
servational studies (Figure 1) confirmed the RCT findings
(pooled OR, 0.80 [CI, 0.63 to 1.02]; P  0.070), al-
though there was substantial heterogeneity (heterogeneity
P  0.004; I2  78%).
Secondary End Points
Individual and pooled ORs for secondary outcomes
are shown in Figures 2 and 3 and Appendix Figure 2
(available at www.annals.org). Two-hundred-eleven of
2799 patients (7.5%) in the early invasive groups had MI
compared with 197 of 2541 patients (7.8%) in the delayed
invasive groups (pooled OR, 1.15 [CI, 0.65 to 2.01]; P 
0.63; heterogeneity P  0.001; I2  82%). Major bleed-
Table 2. Timing of the Invasive Approach, Definitive Treatment, and Clinical Outcomes at Follow-up for Observational Studies

















Early Strategy Delayed Strategy
Sorajja et al, 2010 (17) ACUITY 24 24 4937 2812 PCI: 4937 (100) PCI: 2812 (100) Death, MI, major
bleeding at 12 mo
Ryan et al, 2005 (20) CRUSADE 23.4 46.3 45 548 10 804 PCI: 19 130 (42.0)
CABG: 6103 (13.4)














Death at 6 mo, major
bleeding at hospital
discharge







bleeding at 30 d
ACUITY  Acute Catheterization and Urgent Intervention Triage Strategy; CABG  coronary artery bypass graft; CRUSADE  Can Rapid Risk Stratification of Unstable
Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines; GRACE  Global
Registry of Acute Coronary Events; MI  myocardial infarction; PCI  percutaneous coronary intervention; SYNERGY  Superior Yield of the New Strategy of
Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors.
* Percentages may not sum to 100 due to rounding.
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ing occurred in 78 of 2799 patients (2.8%) in the early
invasive groups and 95 of 2571 patients (3.7%) in the
delayed invasive groups (OR, 0.76 [CI, 0.56 to 1.04]; P 
0.090; heterogeneity P  0.90; I2  0%). Refractory isch-
emia occurred in 103 of 2726 patients (3.8%) in the early
invasive groups and 182 of 2502 patients (7.3%) in the
delayed invasive groups (OR, 0.55 [CI, 0.35 to 0.86]; P 
0.008; heterogeneity P  0.030; I2  60%), and repeated
revascularizations were required by 154 of 2287 patients
(6.7%) in the early invasive groups and 143 of 2053 pa-
tients (7%) in the delayed invasive groups (OR, 0.98 [CI,
0.77 to 1.24]; P  0.86; heterogeneity P  0.69; I2 
0%).
Observational findings for MI suggested greater bene-
fit with early intervention than trial findings but were sta-
tistically heterogeneous (OR, 0.86 [CI, 0.69 to 1.08]; P 
0.190; heterogeneity P  0.001; I2  86%) (Figure 2).
Observational findings for major bleeding suggested poten-
tial for harm with early intervention, unlike trial findings,
but were also statistically heterogeneous (OR, 1.12 [CI,
0.69 to 1.82]; P  0.64; heterogeneity P  0.001; I2 
92%) (Figure 3).
Sensitivity Analyses
Sensitivity analyses, done by removing each of the
studies 1 at a time, demonstrated that no single study
changed the statistical significance of the overall results.
Adding events from the early group in the LIPSIA-
NSTEMI trial to those of the immediate group did not
change the estimates of effect for any outcome.
DISCUSSION
In this update of our previous review and meta-
analysis (4), we added evidence from 2 additional trials and
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ABOARD  Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention;
ACUITY  Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE  Can Rapid Risk Stratification of Unstable Angina Patients
Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines; D-L 
DerSimonian and Laird; ELISA  Early or Late Intervention in Unstable Angina; GRACE  Global Registry of Acute Coronary Events; ISAR-
COOL  Intracoronary Stenting With Antithrombotic Regimen Cooling Off; LIPSIA-NSTEMI  Leipzig Immediate Versus Early and Late Percu-
taneous Coronary Intervention Trial in Non–ST-Segment Elevation Myocardial Infarction; OR  odds ratio; SYNERGY  Superior Yield of the New
Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors; TIMACS  Timing of Intervention in Acute Coronary Syndromes.
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4 observational studies to the estimates we previously re-
ported for outcomes among patients with NSTE-ACS re-
ceiving early compared with delayed invasive intervention.
With the additional evidence, we estimate that early inter-
vention leads to a nonsignificant decrease in mortality rate
compared with delayed intervention. Early intervention
also seems to be associated with a nonsignificant increase in
MI and decrease in major bleeding and statistically signif-
icant decrease in refractory ischemia during follow-up.
Strictly interpreted, the current meta-analysis indicates that
early intervention offers little or no statistically significant
clinical benefit compared with a delayed invasive approach.
However, the CIs around our estimates are wide and in-
clude values compatible with potentially important benefits
and harms of early intervention. Thus, although limited
trial evidence suggests decreases in refractory ischemia with
early intervention, evidence is otherwise inconclusive about
the relative effects of early and late intervention in patients
with NSTE-ACS, and an appropriately powered RCT is
warranted to definitively determine whether early interven-
tion really benefits patients.
Several RCTs and meta-analyses have shown that an
invasive strategy is superior to an initially conservative ap-
proach, in which angiography is done on the basis of clin-
ical or noninvasive evidence of recurrent ischemia (1–3).
With invasive management, an early approach may facili-
tate rapid diagnosis, earlier mechanical revascularization,
and shorter hospital stays; there may also be potential for
early hazard because of intervention on unstable plaques
with fresh thrombus. Conversely, a delayed strategy may
provide benefits through plaque passivation by optimal
medical treatment followed by intervention on more stable
plaques; this potential advantage, however, may be offset
by a higher risk for events while waiting for angiography.
Suggestions of benefit with an early strategy, using the
combined end point of death and MI, mainly come from 2
trials. In ISAR-COOL, in which patients with ischemic
symptoms and ST-segment depression or increased tro-
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ABOARD  Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention;
ACUITY  Acute Catheterization and Urgent Intervention Triage Strategy; CRUSADE  Can Rapid Risk Stratification of Unstable Angina Patients
Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines; D-L 
DerSimonian and Laird; ELISA  Early or Late Intervention in Unstable Angina; ISAR-COOL  Intracoronary Stenting With Antithrombotic
Regimen Cooling Off; LIPSIA-NSTEMI  Leipzig Immediate Versus Early and Late Percutaneous Coronary Intervention Trial in Non–ST-Segment
Elevation Myocardial Infarction; OR  odds ratio; SYNERGY  Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein
IIb/IIIa Inhibitors; TIMACS  Timing of Intervention in Acute Coronary Syndromes.
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ponin levels were randomly assigned to a very early (me-
dian, 2.4 hours) versus delayed (median, 86 hours) invasive
strategy (12), the primary combined end point of death or
large, nonfatal MI at 30 days was increased in patients
having a delayed invasive strategy (11.6% vs. 5.9%). In the
TIMACS (Timing of Intervention in Acute Coronary Syn-
dromes) trial (8), the primary combined end point (death,
new MI, or stroke at 6 months) did not differ significantly
between the early and delayed groups, although a signifi-
cant decrease in the rate of death and MI was seen in the
prespecified subgroup with high GRACE risk scores
(140) having early intervention (14.1% vs. 21.6%). On
the other hand, the OPTIMA trial (13), although under-
powered, suggests an increased risk for MI with early in-
tervention; this trial randomly assigned 142 patients with
ACS eligible for PCI to immediate (0.5 hours) or delayed
(25 hours) PCI; a broad MI definition was used that in-
corporated all MIs in its end point, including evolving
MI at randomization; this was done because, with early
PCI, periprocedural MIs are difficult to differentiate from
spontaneously evolving MIs that started before PCI. The
OPTIMA trial showed that MI rates were significantly
higher in patients receiving early PCI; this difference was
most likely due to an excess of periprocedural MIs in the
immediately treated group. No published trial was pow-
ered to assess a significant difference in survival rate as a
single end point; moreover, most patients included in the
available RCTs were at lower risk, compared with the sub-
group analyzed in the TIMACS trial.
Current international guidelines recommend an early
invasive strategy within 12 to 24 hours for patients with
NSTE-ACS with high-risk features, defined by a GRACE
score greater than 140, and within 72 hours for those at
lower risk, with GRACE scores less than 140 (21, 22); this
recommendation, however, is mainly based on the sub-
group analysis of the TIMACS trial, which was not pow-
ered to answer the question about survival. The IDEAL
NSTEMI (Immediate Versus Early Invasive Approach in
Non–ST-Elevation Myocardial Infarction) is another study
that was planned to compare, in a large sample (2100 par-
Figure 3. Individual and summary ORs for major bleeding complications in randomized trials and observational studies comparing
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ABOARD  Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention;
ACUITY  Acute Catheterization and Urgent Intervention Triage Strategy; D-L  DerSimonian and Laird; ELISA  Early or Late Intervention in
Unstable Angina; GRACE  Global Registry of Acute Coronary Events; ISAR-COOL  Intracoronary Stenting With Antithrombotic Regimen
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Inhibitors; TIMACS  Timing of Intervention in Acute Coronary Syndromes.
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ticipants), an immediate versus early invasive approach but
was withdrawn before enrollment for lack of funding (23).
Two recent meta-analyses (4, 24) were consistent in sug-
gesting no clear-cut survival benefit and fewer major bleed-
ing complications with an early invasive compared with a
delayed approach. These reports, however, did not include
the findings on the high-risk population enrolled in the
LIPSIA-NSTEMI trial (14), which was not yet available,
or the results of an RCT that was not published in English
(16). There was also no systematic analysis of the avail-
able observational studies. In LIPSIA-NSTEMI, 600 high-
risk patients with NSTE-ACS were randomly assigned to
an immediate (2 hours) versus a moderate (24 hours)
versus a delayed (48 hours) strategy; the immediate strat-
egy was not found to offer an advantage in survival or
decreased MI rates over the other 2 strategies. Thus, the
available RCTs were powered to assess differences in com-
posite rather than individual end points (mainly death, MI,
or stroke); although these study designs enabled a decrease
of sample size, treatment effects varied largely across end
points and individual components.
Moreover, the wide CI around the pooled OR for
mortality in our meta-analysis reflects the small overall
sample size, the inclusion of several small RCTs, the low
event rates, and the fact that a single trial contributed to
most events. In addition, heterogeneity was found across
studies in the timing of intervention, definitions of MI and
major bleeding, and patients’ risk profiles. Thus, the inter-
pretation of the survival results has varied from positive
(based on the subgroup analysis of the composite end point
in TIMACS) to negative (based on the previous meta-
analyses) to nonconclusive, as shown by the present com-
prehensive report. This uncertainty contrasts with the cur-
rent guideline recommendations (21, 22).
To definitively answer the question of a potential sur-
vival benefit with early compared with later intervention,
we estimate that an RCT would require approximately
7807 patients per group (a total of 15 614 patients) to have
80% statistical power and approximately 10 450 per group
(a total of 20 900 patients) to have 90% statistical power to
detect the 30-day mortality decrease estimated in this anal-
ysis (OR, 0.80, translating into a 1% absolute difference in
favor of early intervention, assuming the absolute mortality
rate of 4.7% seen in the late intervention groups) with a
2-sided  of 0.05. In the setting of ST-segment elevation
MI, the GUSTO-I (Global Utilization of Streptokinase
and Tissue Plasminogen Activator for Occluded Coronary
Arteries) trial compared streptokinase plus intravenous
heparin against recombinant tissue–type plasminogen acti-
vator plus intravenous heparin (25). The primary end
point was 30-day mortality; with approximately 10 350
patients per group, 30-day death rates were 7.4% for strep-
tokinase versus a significantly lower 6.3% rate for the re-
combinant tissue–type plasminogen activator, which led to
the recommendation of a recombinant tissue–type plas-
minogen activator as preferred thrombolytic strategy (26).
Similarly, detection of a 1% absolute difference in mortal-
ity with an early versus a delayed invasive strategy in the
management of the large NSTE-ACS population (which is
larger than that of patients with ST-segment elevation MI,
numbering millions per year worldwide and increasing as a
result of the growing and aging population) could have
important clinical implications. It is conceivable that the
absolute mortality difference between the 2 strategies may
increase with longer follow-up; indeed, the post hoc timing
analysis of the ACUITY trial suggests greater survival ben-
efit at 1 year than at 30 days with early compared with
delayed intervention (17). In the present meta-analysis of
RCTs, the maximum length of follow-up for death was 6
months, and we believe that a future trial should extend its
follow-up to 1 year. The population to be included in such
a trial should reflect the real-world population, focusing on
high-risk groups that may derive the greatest survival ben-
efit with the early approach; the currently available studies
(except for LIPSIA-NSTEMI, which was not powered to
assess mortality differences) included a substantial portion
of patients (ranging from 33% to 54%) without elevated
plasma troponins, indicating a low-risk population. To
date, all of the studies on timing of intervention in patients
with NSTE-ACS were conducted using variable loading
doses of 300 to 600 mg of clopidogrel; new, more potent,
and rapidly acting antiplatelet agents (prasugrel or ticagre-
lor), as well as safer anticoagulants (such as bivalirudin), are
now recommended by guidelines and may be crucial in
modulating the relationship between timing of interven-
tion and clinical outcome; ideally, a future RCT should
plan appropriate concomitant adjunctive medical therapy.
Secondary end points should include careful appraisal of
MI, stratified by time of occurrence (during index hospi-
talization vs. follow-up) and major bleeding.
In conclusion, the current available evidence does not
allow firm conclusions to be drawn in favor of or against an
early invasive approach in the NSTE-ACS population. A
more definitive RCT, properly powered for mortality as
the single end point, and related cost-effective analyses are
warranted to quantify the potential survival benefits and
assess the feasibility of an early approach in patients with
NSTE-ACS.
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Appendix Figure 1. Summary of evidence search and
selection.
Studies assessed according






Studies excluded according to 
explicit selection criteria (n = 11)
RCTs comparing routine 




Time frame of invasive 
approach not reported: 1
Early vs. conservative 
approach: 1





Abstracts of conference 
proceedings: 2
Studies included in meta-analysis 
(n = 11)
RCTs previously reported: 5 
(4155 patients) (reference 4)
RCTs new to update: 2     
(1215 patients)
Observational studies: 4 
(77 499 patients)
RCT  randomized, controlled trial.
Appendix Table 1. Full Electronic Search in MEDLINE Database Through May 2012
Search Query Items Found, n
12 Search early coronary intervention AND delayed coronary intervention AND acute coronary syndrome 25
11 Search acute coronary syndrome AND timing 170
8 Search acute coronary syndrome AND early PCI 219
7 Search acute coronary syndrome AND early coronary angioplasty 399
6 Search acute coronary syndrome AND early coronary intervention 499
5 Search ACS AND coronary invasive 484
4 Search NSTE-ACS AND coronary invasive 123
3 Search NSTEMI AND coronary invasive 119
2 Search non-st-elevation myocardial infarction AND coronary invasive 208
1 Search acute coronary syndrome AND coronary invasive 859
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Appendix Table 4. Risk of Bias of Included Randomized, Controlled Trials

























Mehta et al, 2009 (8) TIMACS Yes Yes Yes No No Yes Yes No Yes
Montalescot et al, 2009 (11) ABOARD Yes Yes Yes No No Yes Yes No Yes
Neumann et al, 2003 (12) ISAR-COOL 2 sites Yes Yes No No Yes Yes No Yes
Riezebos et al, 2009 (13) OPTIMA Yes Unclear Unclear No No Unclear Yes No Yes
Thiele et al, 2012 (14) LIPSIA-NSTEMI Yes Yes Yes No No Yes Yes No Yes
van ’t Hof et al, 2003 (15) ELISA No Yes Yes No No Yes Yes No Yes
Zhang et al, 2010 (16) NA Yes Unclear Unclear No No Yes Yes No Yes
ABOARD  Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention; ELISA  Early or Late
Intervention in Unstable Angina; ISAR-COOL  Intracoronary Stenting With Antithrombotic Regimen Cooling Off; LIPSIA-NSTEMI  Leipzig Immediate Versus Early
and Late Percutaneous Coronary Intervention Trial in Non–ST-Segment Elevation Myocardial Infarction; NA  not applicable; TIMACS  Timing of Intervention in
Acute Coronary Syndromes.
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Appendix Figure 2. Individual and summary ORs for refractory ischemia and repeated revascularization in patients treated with








Zhang et al, 2010 (16)
Total
Heterogeneity: τ2 = 0.17; chi-square = 12.50; P = 0.030; I2 = 60%








































D-L, Random (95% CI)
OR
D-L, Random (95% CI)














Zhang et al, 2010 (16)
Total
Heterogeneity: τ2 = 0.00; chi-square = 1.46; P = 0.69; I2 = 0%
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ABOARD  Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention; D-L 
DerSimonian and Laird; ELISA  Early or Late Intervention in Unstable Angina; ISAR-COOL  Intracoronary Stenting With Antithrombotic
Regimen Cooling Off; LIPSIA-NSTEMI  Leipzig Immediate Versus Early and Late Percutaneous Coronary Intervention Trial in Non–ST-Segment
Elevation Myocardial Infarction; OR  odds ratio; TIMACS  Timing of Intervention in Acute Coronary Syndromes.
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